Download - Bionest Partners Capabilities Summer 2009
1
Strategic Advice and Beyond
Summer 2009
2
A unique A unique blend of management consulting and financial advisory servicesblend of management consulting and financial advisory services
"We combine strategic thinking with extensive real world experience to provide operational solutions which will help you to achieve your business goals"
Bionest Partners Leadership Team
� Corporate development
� Product strategy/portfolio management
� Commercialization strategy
� Implementation support
� Mergers and acquisitions
� In- and out-licensing
� Pipeline and company valuation
� Private placement
Management Consulting Financial Advisory Services
Bionest is exclusively dedicated to life sciencesBionest is exclusively dedicated to life sciences
Over 250 clients
� Extensive network
� Industry experts & executives
� Regulatory experts & healthcare officials
� Key Opinion Leaders
PHARMA
BIOTECHS
INVESTORS
3
�Global reach
� Europe (Paris) and USA (New York)
� 35 experienced consultants
� Combining healthcare, strategy and
banking backgrounds
Life sciences only
4
Capabilities and track record built around six areas of expertisCapabilities and track record built around six areas of expertisee
Medical Devices
Rx/Generics/Biosimilars/OTC
Diagnostics
Healthcare Services
Animal Health
Vaccines
5
Bionest bridges the gap between strategy and finance Bionest bridges the gap between strategy and finance
� Roll-out plans / Key Performance Indicators (KPI)
� Commercial organization effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
Corporate Development
Management Consulting Financial Advisory Services
P 7
P10
P 12
P 14
P 17
P 19
� Roll-out plans / Key Performance Indicators (KPI)
� Commercial organization effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
Corporate Development
Management Consulting Financial Advisory Services
P 7
P 10
P 12
P 14
P 17
P 19
Case Studies1
Management Consulting Case Management Consulting Case StudiesStudies
7
� Roll -out plans / Key Performance
Indicators (KPI)
� Commercial organization
effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone ” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales
forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Management Consulting Financial Advisory Services
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
� Roll -out plans / Key Performance
Indicators (KPI)
� Commercial organization
effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone ” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales
forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Management Consulting Financial Advisory Services
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
8
Product Strategy / Portfolio Management (1/2)Product Strategy / Portfolio Management (1/2)
We helped We helped SavientSavient toto
size up the value of the size up the value of the
European market European market
opportunity and position opportunity and position
PuricasePuricase ®®
Bionest impact
� Savient is a US specialty biopharma
� Bionest provided all inputs required to build a preliminary model
of a stand alone European commercialization strategy for Phase
III Puricase®
� Key work streams included the gout market, competitive
landscape, physicians’ feedback, sales forecasts…
� Bionest accompanied Savient on the investor road show
Market assessment
June 2007
Attitude Awareness
and Use study
Sales forecast model
Developed an IV product
for gout treatment a
market without innovation
for 40 years
Assignment overview
� Javelin is a US company that applies innovative proprietary
technologies to develop new drugs and improve formulations
of existing drugs
� Bionest evaluated the best target price for the product to
enable ideal positioning in Europe by analyzing:
� Payors’ value drivers
� Optimal and effective price in the G5
� Market size and market share
� Pan-European pricing strategy
Other clients
Market assessment Assignment overview
Bionest carried out a detailed Bionest carried out a detailed
pricing study which confirmed pricing study which confirmed
that the new IV that the new IV diclofenacdiclofenac
formulation could command a formulation could command a
much higher price against much higher price against
generic competitiongeneric competition
Bionest impact
August 2006
Developed an innovative
IV diclofenac for a post
operative pain product
Attitude Awareness and
Use Study
Pricing&Reimbursement
study
July 2008
US big pharma
Clinical and commercial
strategy assessment
9
Product Strategy / Portfolio Management (2/2) Product Strategy / Portfolio Management (2/2)
We enabled Bayer Schering Pharma to develop the best
global strategy for its oncology franchise over the
next 5 years
Bionest impact Product strategic plans Assignment overview
� Large US pharmaceutical with significant pipeline but lack of
experience in oncology
� For each compound, Bionest:
� Developed full scenario-based forecasts taking into
account market dynamics, trials data and competitive
landscape
� Recommended optimal commercialization strategies
for targeted patient segmentation, unmet needs, most
favorable NPV and strategic fit within the organization
Clinical development strategy
Assignment overview
Bionest helped to maximize Bionest helped to maximize
value creation through an value creation through an
accurate rankingaccurate ranking
of portfolio products of portfolio products
Bionest impact
2007 - 2008
Strategy, operations
and organization
Oncology franchise
strategic plan
- 10 cancer indications
- 8 products
Other clients
� 8 Product strategic plans for
� Fully documented situation assessments
� Resulting key event grids, product SWOT analyses and
formulation of key challenges
� Product strategy encompassing scenario planning,
contingency plan, product ambition, One Page Strategy,
product positioning, targeting strategy & investment
priorities
� Product action plans including “quick wins” and
resulting P&Ls
� Resource allocation exercise
� Development of Oncology franchise strategy, including
organizational effectiveness
Management Consulting Case Studies
� Roll-out plans / Key Performance
Indicators (KPI)
� Commercial organization
effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales
forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Management Consulting Financial Advisory Services
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
� Roll-out plans / Key Performance
Indicators (KPI)
� Commercial organization
effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales
forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Management Consulting Financial Advisory Services
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
10
11
Commercialization StrategyCommercialization Strategy
Bionest constructed an initial organizational structure for the product
launch in Europe
Bionest impact Go-it-alone strategy Assignment overview
Operational roadmap Assignment overview
Bionest developedthe ex US worldwide launch strategy for the Flumist
vaccine, for Medimmune and Astra Zeneca
Bionest impact
October 2007
Flu vaccine
Ex-US
commercialization
strategy
March 2007
Testing a go-it-alone
strategy
Go it alone strategy
evaluation for the launch
of oritavancin in Europe
� Targanta, acquired by The Medicine Company in January 2009, is
a US biopharmaceutical company
� Bionest provided Targanta with:
� Strong data for the board to make a go/no go decision
� The first model of their European organization
� Strategic, operational/practical and tactical
recommendations as the basis of a detailed roll-out plan
by country
� The commercial infrastructure of Medimmune, acquired in 2007 by
Astra Zeneca, is limited to the US
� Built detailed forecast and prioritization models for 32 ex-US
countries
� Physicians and payors’ perception of the product
� Key Opinion Leaders interviewed for influenza
� Opportunity assessment 14 markets, EU, Asia, Latin America
� Resourcing of ex-US launch through workshop sessions with
affiliates of Europe, Asia and Latin America
Other clients
Management Consulting Case Studies
12
� Roll-out plans / Key Performance
Indicators (KPI)
� Commercial organization
effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales
forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Management Consulting Financial Advisory Services
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
� Roll-out plans / Key Performance
Indicators (KPI)
� Commercial organization
effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales
forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Management Consulting Financial Advisory Services
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
13
Implementation Support
We provided Idenix with a turn-key solution to be ready in time for EMEA
filing and launch
Bionest impact Commercial organization
effectivenessAssignment overview
Commercial organization effectiveness
Assignment overview
Bionest helped Paionto open discussions
with Lundbeck’s team and capture Lundbeck’s vision on
Desmoteplase com-mercialization
Bionest impact
� Idenix needed to build a European co-promotion infrastructure
from scratch for their HBV phase III product
� Bionest assessed key strategic issues for commercializing a
Hepatitis B product in Europe
� Assessed future EU HQ location and designed required
infrastructure, quantified associated investments
� Developed a detailed implementation road map and supported
company setup (e.g. identified subcontractors)
Desmoteplase
co-promotion strategy
for EU G5
� Involved in a co promotion agreement with the big pharma
Lundbeck, German biotech Paion gave these key assignments to
Bionest:
� Desmoteplase’s "ideal" and "realistic" sales force sizing
� Identification of co-promotion organizational models
� Preparation and facilitation of a joint workshop meeting to
address Desmoteplase’s sales force organization
Other clients
October 2007
HBV treatment
Ex-US
commercialization
strategy
2007
Corporate Development Case Studies
� Roll-out plans / Key Performance
Indicators (KPI)
� Commercial organization
effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales
forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Management Consulting Financial Advisory Services
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
� Roll-out plans / Key Performance
Indicators (KPI)
� Commercial organization
effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales
forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Management Consulting Financial Advisory Services
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
14
15
Corporate DevelopmentCorporate Development
In 3 weeks, Bionest was able In 3 weeks, Bionest was able
to provide 4SC with a BUY to provide 4SC with a BUY
recommendation for recommendation for
NycomedNycomed’’ss preclinical oncology preclinical oncology
portfolioportfolio
Bionest impact Opportunity assessment Assignment overview
Global strategic review Assignment overview
Bionest developed a crystal Bionest developed a crystal
clear road map to share with clear road map to share with
the management, the board the management, the board
and the shareholders and the shareholders
Bionest impact
� In November 2007, Nycomed announced its intention to divest a
portfolio of oncology products, encompassing three HDAC
inhibitors (Phase I and PC) and several other early compounds
� The Germany-based 4SC company solicited Bionest to conduct
an in-depth assessment of each drug candidate as well as the
valuation of the portfolio
� Bionest Partners provided a “buy” recommendation and 4SC
submitted a successful bid including a total consideration of
€14m in cash
� Exonhit is a French-American biotech company that develops
applications of its proprietary gene profiling technology in the
diagnostic/ therapeutic areas
� A new CEO was appointed in July 2008, whose mission was to lay
out the vision and the business model of the Company for the
next 5 to 10 years
� ExonHit asked Bionest Partners to help the Company analyze its
potential future from the science & technology, commercial and
financial angles
� ExonHit also wanted to assess the impact of new business
models on financial market valuation.
December 2008
Global strategic
review
Rx / Dx
April 2008
Assessment of
product franchise
Oncology
Other clients
16
Bionest was able to act swiftly for this major transaction, not only
assessing the business plan but educating the PE team about the generic market
place
Bionest impact Strategic due diligence Assignment overview
Strategic due diligence
Bionest contributed significantly to the understanding of the
European medicated feed additives market and its
evolution over time
Bionest impact
2008
Commercial due
diligence
Bid for
� Bionest acted as commercial due diligence provider for the
Apax/Bain Capital consortium
� Bionest answered clients’ needs through desk research,
interviews with clients, competitors, industry associations and
government representatives on an international basis
� For a 2-month period, key work streams included:
� Determine the attractiveness of each generics/branded
market
� Evaluate the competitive position of Merck by country
� Assess the defensibility of Merck’s position in each market
2008
Commercial due diligence
for
� Working closely with 3i, Bionest combined extensive secondary
and primary research to provide the most current view of the
European animal health industry dynamics and develop a rigorous
set of combinations with Phibro’s business from a build-up
perspective
� To meet these objectives, Bionest followed a two-step approach:
� Global review of AH segments attractiveness in Europe,
especially nutritional feed additives
� Assessment of business and industrial options for Phibro
in view of European expansion
Corporate DevelopmentCorporate Development
Assignment overview
Other clients
Financial Advisory Case Studies
� Roll-out plans / Key Performance
Indicators (KPI)
� Commercial organization
effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales
forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Management Consulting Financial Advisory Services
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
� Roll-out plans / Key Performance
Indicators (KPI)
� Commercial organization
effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales
forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Management Consulting Financial Advisory Services
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
17
18
MergersMergers & Acquisitions / & Acquisitions / LicensingLicensing
Bionest was able to rapidly Bionest was able to rapidly
secure a transforming deal secure a transforming deal
with an with an ““outout--ofof--thethe--boxbox””
buyerbuyer
Bionest impact M&A Assignment overview
Licensing Assignment overview
Bionest supported EUSA Bionest supported EUSA
PharmaPharma in the outin the out--licensing of licensing of
a preclinical anti ILa preclinical anti IL--6 to GSK 6 to GSK
for $44million for $44million
Bionest impact
� The French health authorities decided to stop reimbursing
venotonic agents as of 1 January 2008
� French pharmaceutical company Ipsen did not wish to enter the
OTC market and decided to divest Ginkor Fort to a company
offering a better fit
� On 23 August 2007, Ipsen announced the out-licensing of Ginkor
Fort French distribution rights to Groupe GTF, a specialist in the
management of mature products via its subsidiary Tonipharm
� EUSA Pharma is a transatlantic specialty pharmaceutical company
focused on in-licensing, developing and marketing late-stage
oncology, pain control and critical care products
� As part of the company’s 2007 acquisition of France-based OPi,
EUSA Pharma acquired OP-R003, the first fully human anti-
interleukin-6 (IL-6) antibody developed for oncology and
inflammatory diseases, at a preclinical stage of development
� In February 2008, EUSA Pharma announced the global and
exclusive out-licensing of OP-R003 to GSK for a consideration of up
to $44m (upfront fee, development milestones plus royalties on
future sales)
February 2008
Sole Advisor
Out-licensed
OP-R003 Full Rights to
August 2007
Sold Ginkor Fort to
Exclusive Advisor
Other clients
Financial Advisory Case Studies
� Roll-out plans / Key Performance
Indicators (KPI)
� Commercial organization
effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales
forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Management Consulting Financial Advisory Services
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
� Roll-out plans / Key Performance
Indicators (KPI)
� Commercial organization
effectiveness
� Initiation of operations
Implementation Support
Commercialization Strategy
� Market Access
� “Go-it-Alone” versus partnering
strategy evaluation
� Blueprint for organizational
structure
Product Strategy
� Competitive positioning
� Clinical development strategy
� Market assessment & sales
forecast
� Product strategic plans
� Portfolio management
M&A/Licensing
� Acquisition advisory
� Divestment advisory
� Target identification
� Assistance in negotiations
Valuation/Placement
� Value drivers identification
� Business plan
� Financial analysis
� Fund raising
Management Consulting Financial Advisory Services
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
Corporate Development
� Strategic scenarios review
� Opportunity assessment
� Resource allocation
� Spin off/carve out support
� Strategic due diligence
19
20
ValuationValuation / Placement / Placement
In two weeks, Bionest In two weeks, Bionest
implemented standard as implemented standard as
well as creative and easywell as creative and easy--
toto--read resultsread results to perform to perform
the company valuationthe company valuation
Bionest impact Valuation Assignment overview
Placement Assignment overview
Bionest actively contributed Bionest actively contributed
to the closing of a to the closing of a €€15m 15m
placement by delivering a placement by delivering a
simple yet attractivesimple yet attractive
equity storyequity story
Bionest impact
� Mutabilis is a France-based biopharmaceutical company
specialized in the anti-infectious field
� In view of a forthcoming fundraising round, Mutabilis mandated
Bionest to conduct an independent valuation of the company
� As decided together with management, Bionest approached the
valuation of Mutabilis solely based on a benchmark approach (no
DCF analysis was performed on the Mutabilis products and
technology platforms)
� By using five benchmark-based valuation methods, Bionest was
able to derive a realistic valuation range
� Genfit is a French biopharmaceutical company focused on the
treatment of cardiometabolic disease
� Oddo Corporate Finance and Bionest Partners acted as co-
advisors to Genfit
� Prior to the IPO, the company successfully completed a private
placement of €15 million amongst several qualified investors as
well as historical shareholders
� Bionest produced an in-depth analyst report, positioning Genfit
as a highly differentiated player in the biotechnology field
December 2007
Independent
corporate valuation
Exclusive Advisor
December 2006
Raised €15m
Listed on Alternext
Co-Advisors
Other clients
Selected Publications2
Major publications by Bionest Major publications by Bionest PartnersPartners
200720072008 2008 2008
20082008200820082009
22
Partners and Managers Biographies3
� Before joining Bionest as a Managing Partner, Frédéric was head of Pharma Equity Research and a partner at Exane BNP Paribas, Paris
� Previously head of a research team at GlaxoWellcome (Les Ulis, France) - research and preclinical development in cardiovascular diseases; Scientific
Consultant for Hoechst (Sommerville, USA) Advisor for the R&D team in neurodegenerative disorders (i.e. Alzheimer’s)
� Guest Investigator at Rockefeller University (New York, USA) conducting research on biochemical and cellular aspects of Alzheimer’s disease in Paul
Greengard’s laboratory (Nobel Prize for Medicine, 2000)
Frédéric Desdouits – Managing Partner, PhD, MSc., CEFA
Management team Management team -- PartnersPartners
� Co-founder of Bionest in 2003
� Previously European Founding President of Biogen Inc, (BGEN) where he was responsible for the launch of Avonex®
� Held several positions at senior management level such as European founder of IDEXX Labs Inc, President of Medtronic Europe
� Started his career in sales and marketing at Abbott’s Diagnostic Division and remained there for 17 years
� At Bionest, Alain is mostly involved in Biopharmaceutical, Animal Health, Product Launch, Private Equity and very focused on the USA
Alain J. Gilbert – Managing Partner
� Before co-founding Bionest in 2003, Claude was a ISO HealthCare Consulting VP in Paris (1998-2002), responsible for developing the European
healthcare and biotechnology consulting services and Senior consultant specialized in Healthcare for Arthur D. Little (1991-1998)
� He led over 200 projects in R&D, Marketing and Sales, Medical Affairs, and Business Development, in Europe and North America, for Big Pharma and
growing biopharmaceutical firms.
� Prior to consulting, Claude held a number of Corporate and Operational Finance / Marketing positions for 14 years with Glaxo PLC International,
Rhône-Poulenc Santé International and Parke-Davis France.
� Claude graduated from ESSEC and is a member of SFAF (Société Française des Analystes Financiers)
Claude Allary – Managing Partner , MBA, CEFA
24
25
Management team Management team -- Managers Managers
� Former London-based investment banker with Robertson Stephens and Bank of America Securities
� Before joining Bionest in 2004, spent over eight years specializing in US and European healthcare (Biotech, Spec Pharma, Pharma, Med Tech)
� Mandates mainly covered M&A (both buy-sides and sell-sides) and Private Placements
Catherine Pichereau – Manager, MSc.
� Over 5 years of Consulting experience at Bionest Partners where he has been involved and/or managed over 50 projects
� Worked on a large range of projects: Strategic positioning, business planning, strategic due diligences
� Gained experience at Genopole (Evry, France), French Trade Commission (Toronto, Canada)
� Obtained a Master’s in Life Sciences and Management from ISTM (Paris)
Thomas Martinelli – Manager
� Before Bionest, gained 10 years of management experience in strategic and organizational consulting dedicated to the Healthcare Industry
� Before entering consultancy, held several key operational positions at IMS Health
� Consulting expertise developed around strategic, operational and organizational issues
Lionel Delaporte – Managing Director
26
19, rue du Général Foy75008 Paris
France
Tel: +33 1 58 05 14 00Fax: +33 1 58 05 14 09
Tower 49, 12th floor12 East 49th StreetNew York, NY 10017
USA
Tel: +1 646 386 2900Fax: +1 212 832 3227
www.bionest.com